Novartis Seeks To Nix Expert Testimony In Bone Drug MDL

Law360, New York (May 20, 2011, 3:30 PM EDT) -- Novartis Pharmaceuticals Corp. asked a Tennessee federal judge on Thursday to exclude six experts' testimony in 30 suits in a multidistrict litigation over the bone cancer drugs Aredia and Zometa, the same day it sought to dismiss four of those cases.

The lawsuits in the MDL, which was consolidated in April 2006 and has involved hundreds of suits, accuse Novartis of failing to warn patients that its drugs Aredia and Zometa could cause osteonecrosis of the jaw, a condition involving the deterioration of the jawbone....
To view the full article, register now.